Concurrent celecoxib versus placebo in patients with stage II-III non-small cell lung cancer: A randomised phase II trial

被引：12

作者：

De Ruysscher, Dirk

Bussink, Johan

Rodrigus, Patrick

Kessels, Alfons

Dirx, Miranda

Houben, Ruud

Wanders, Rinus

机构：

[1] Univ Hosp Maastricht, Dept Radiat Oncol, GROW, NL-6229 ET Maastricht, Netherlands

[2] MAASTRO Clin, Maastricht, Netherlands

[3] Radboud Univ Nijmegen, Med Ctr, Dept Radiat Oncol, Nijmegen, Netherlands

[4] Bernard Verbeeten Inst, Tilburg, Netherlands

[5] Univ Hosp Maastricht, Dept Hlth Technol Assessment, Maastricht, Netherlands

[6] Comprehens Canc Ctr Limburg, Maastricht, Netherlands

来源：

RADIOTHERAPY AND ONCOLOGY | 2007年 / 84卷 / 01期

关键词：

COX-2; celecoxib; randomised; phase II; NSCLC; radiotherapy;

D O I：

10.1016/j.radonc.2007.05.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In several pre-clinical models, cyclooxygenase (COX) inhibitors increase radio-sensitivity of tumours, whilst not affecting normal tissues. A randomised phase II trial comparing concurrent radiotherapy with either celecoxib or placebo in patients with stage II-III non-small cell lung cancer was therefore initiated. Because of poor recruitment, the study was stopped after the enrollment of 41 patients, instead of the foreseen 102. None of the endpoints differed significantly between both groups. However, due to the limited number of patients, no definitive conclusions can be drawn. (c) 2007 Elsevier Ireland Ltd. All rights reserved.

引用

页码：23 / 25

页数：3

共 20 条

[1]

DAWSON SJ, 2006, IN PRESS INVEST NEW

[2] Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials [J].